Anemia Management News

Sanguina has launched a study to examine how its smartphone app that measures hemoglobin levels, known as AnemoCheck Mobile, can be customized for use by patients with chronic kidney disease-related anemia.

Akebia Therapeutics Inc. has submitted a new drug application to the FDA for vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in both adult patients on dialysis and not on dialysis.

A study of patients on hemodialysis found pegloticase was successful in treating gout, while also demonstrating the potential to lower erythropoiesis-stimulating agent dose requirements following the therapy.

Research investigating the mechanisms of anemia in patients with chronic kidney disease, as well as optimal management strategies, is ongoing, according to a speaker at the Annual Dialysis Conference.

The FDA will hold an advisory meeting to review the new drug application for roxadustat, days ahead of the agency’s planned date for approval of the anemia drug, according to a company press release.

Patients with sickle cell disease-related kidney failure experienced similar reductions in mortality following transplantation as those whose kidney failure stemmed from other causes, according to researchers from Johns Hopkins.

FibroGen Inc. announced on Friday that the FDA is delaying a final review of the drug maker’s oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor – roxadustat – for 3 months.

Patients with iron deficiency anemia and chronic kidney disease had increased hemoglobin levels with ferric citrate regardless of the dose they received, according to study findings presented at the virtual ASN Kidney Week.

Vadadustat did not meet the primary safety endpoint of the PRO2TECT program for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease, according to data presented at ASN Kidney Week.

Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and co-chair of the Nephrology News & Issues Editorial Advisory Board, talked about a subanalysis presented at ASN Kidney Week on roxadustat.